Cargando…
In vivo evaluation of [(18)F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography
Development of hypoxia-targeted therapies has stimulated the search for clinically applicable noninvasive markers of tumour hypoxia. Here, we describe the validation of [(18)F]fluoroetanidazole ([(18)F]FETA) as a tumour hypoxia marker by positron emission tomography (PET). Cellular transport and ret...
Autores principales: | Barthel, H, Wilson, H, Collingridge, D R, Brown, G, Osman, S, Luthra, S K, Brady, F, Workman, P, Price, P M, Aboagye, E O |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409496/ https://www.ncbi.nlm.nih.gov/pubmed/15150578 http://dx.doi.org/10.1038/sj.bjc.6601862 |
Ejemplares similares
-
In vitro selectivity, in vivo biodistribution and tumour uptake of annexin V radiolabelled with a positron emitting radioisotope
por: Collingridge, D R, et al.
Publicado: (2003) -
Imaging tumour hypoxia with positron emission tomography
por: Fleming, I N, et al.
Publicado: (2015) -
Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for Pre-phase I positron emission tomography studies in cancer patients
por: Aboagye, E O, et al.
Publicado: (2002) -
Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin
por: Liu, D, et al.
Publicado: (2002) -
Vascular Imaging With (18)F-Fluorodeoxyglucose Positron Emission Tomography Is Influenced by Hypoxia
por: Joshi, Francis R., et al.
Publicado: (2017)